🔗 Share this article The Global Health Body Sounds Warning Over Severe Scarcity of Obesity Injections Less than one in 10 individuals that would benefit from GLP-1 drugs such as Wegovy have access to them, states the World Health Organization as it issues its first recommendations on the medications. Considering over a billion people worldwide now classified as obese, it is advocating for increased and just availability to this class of drugs. According to forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken. "The latest guidelines affirms that excess weight is a lifelong illness that can be treated with holistic and lifelong support," said its chief Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and distribution challenges are significant obstacles to universal access to the jabs that can help people shift substantial body mass, notes the organization. Skinny Jab Shortage Even in the current most optimistic outlook, the manufacturing of such drugs could only cover approximately 100 million people – less than 10% of those who need them, according to the health organization. The recommendation calls on governments and firms to expand access, through measures including voluntary licensing. A patent on semaglutide – the core ingredient of the drug Wegovy – is due to expire in several countries in 2026. How Obesity Injections Function The injections replicate a natural hormone to reduce digestion speed, reduce hunger and boost the sense of being full so individuals reduce food intake. Patients usually begin shedding pounds in the initial weeks of beginning the weekly injections. Studies points to patients may see weight return within a year of stopping the medication, as their usual food cravings come back. Being overweight or obese elevates your risk for developing diseases, such as type 2 diabetes, heart disease, brain attack, and certain cancers. Obesity affects people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
Less than one in 10 individuals that would benefit from GLP-1 drugs such as Wegovy have access to them, states the World Health Organization as it issues its first recommendations on the medications. Considering over a billion people worldwide now classified as obese, it is advocating for increased and just availability to this class of drugs. According to forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken. "The latest guidelines affirms that excess weight is a lifelong illness that can be treated with holistic and lifelong support," said its chief Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and distribution challenges are significant obstacles to universal access to the jabs that can help people shift substantial body mass, notes the organization. Skinny Jab Shortage Even in the current most optimistic outlook, the manufacturing of such drugs could only cover approximately 100 million people – less than 10% of those who need them, according to the health organization. The recommendation calls on governments and firms to expand access, through measures including voluntary licensing. A patent on semaglutide – the core ingredient of the drug Wegovy – is due to expire in several countries in 2026. How Obesity Injections Function The injections replicate a natural hormone to reduce digestion speed, reduce hunger and boost the sense of being full so individuals reduce food intake. Patients usually begin shedding pounds in the initial weeks of beginning the weekly injections. Studies points to patients may see weight return within a year of stopping the medication, as their usual food cravings come back. Being overweight or obese elevates your risk for developing diseases, such as type 2 diabetes, heart disease, brain attack, and certain cancers. Obesity affects people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.